Search
/node/1371
ALK, Learn more about us, GettyImages-484680118_Banner-min.jpg, Pioneering in the field of respiratory allergies for more than a century, we've embarked on a mission to help more people, with more solutions, more e
,
News, http://ir.alk.net/releases.cfm
,
ALK corporate strategy 2024-2028, Strategy+_logo_homepage (1).png, Read more about our corporate strategy, 100 years of pioneering allergy solutions, 100y_book_cover.jpeg, Read now, The hunt for a vaccine – a podcast in five episodes, 2023-06-07_12-44-17.…,
We are the pioneers of allergy solutions, Read more about our corporate strategy, <p><iframe width="660" height="371" src="https://www.alk.net/sites/default/files/2025-03/ALK_purpose%20video%20Aller, Homepage-video-thumbn…,
.main-container-video-headline {
justify-content: center;
align-items: center;
}
.subheading-container {
width: max-content;
}
.subheadin
,
.cards {
max-width: 1200px;
display: flex;
justify-content: space-between;
gap: 30px;
}
.card {
box-shado
,
div.field-item:has(section.paragraphs-item-nasdaq-news) {
background: #F7F7F7;
}
.paragraphs-item-nasdaq-news .views-field-field-link a {
ba
/careersold
Do you want to join ALK?, Careers, Career New Background Image.png, Vacant positions
,
The chance to learn, The opportunity to lead, A world of possibilities
,
Do you want to make a difference?, Left, With almost a century of experience, nobody knows allergy like us, and nobody is more dedicated to making a difference for the millions of people with, careers_text_related_img_1.jpeg, See all vacant positions at A…
/our-company/strategy
ALK strategy 2028, Strategy banner final version-min3.jpg, Focus
,
.h2-strategy-heading {
margin: 0;
font-weight: 600;
font-family: Vertigo;
font-size: 35px;
color: #0a2455;
}
@media (min-width: 1024p
,
Allergy is the most common chronic disease globally and it has profound impact on people’s lives. More than 500 million people worldwide live with res
,
.container {
display: flex;
}
.text-column,
.image-column {
flex: 1;
}
.image-column img {
width: 100%;
height: auto;
}
.image-colu
,
.primary-image-one {
aspect-ratio: 1 / 1;
width: 75% !important;
height: auto !important;
}
.secondary-image-one {
,
.primary-image-two {
aspect-ratio: 1 / 1;
width: 85% !important;
height: auto !important;
margin-left: auto;
}
.secondary-image-two {
,
.primary-image-three{
aspect-ratio: 1 / 1;
width: 70% !important;
height: auto !important;
margin-left: auto;
margin-top: auto;
}
.s
,
.primary-image-four{
aspect-ratio: 1 / 1;
width: 70% !important;
height: auto !important;
margin-left: auto;
margin-top: auto;
}
.se
,
.container-text-image {
display: grid;
grid-template-columns: 1fr 1.1fr;
column-gap: 6%;
}
.container-heading-subheading {
grid-column:
/our-science/healthcare-professionals/clinical-trials
Healthcare professionals, Clinical trials, Clinical Trials moved position.png, OUR KEY SLIT TRIALS
,
a {
color: #002559;
}
.h3-clinical-trials-heading {
font-size: 30px;
color: #002559;
font-weight: 300;
}
.h3-clinical-trials-alt-h
,
Our key SLIT-tablet randomised controlled trialsOur SLIT-tablets build on the legacy of subcutaneous immunotherapy, which was discovered in the early
,
.cards {
max-width: 1200px;
display: flex;
justify-content: space-between;
gap: 30px;
}
.card {
box-shado
,
.clinical-trials-card-container {
display: flex;
gap: 40px;
justify-content: center;
max-width: 1200px;
margin: 10px auto 0 a
,
P05239Disease area: Allergic rhinoconjunctivitisPhase: IIIFollow-up: Single-seasonRegion: North AmericaAge group: Children and adolescentsNo. of parti
,
Tree SLIT-tabletTT-03Disease area: Allergic rhinoconjunctivitisPhase: IIFollow-up: 24 weeksRegion: Environmental exposure chamber (Europe)Age group: A
,
Ragweed SLIT-tabletP05233Disease area: Allergic rhinoconjunctivitisPhase: II/IIIFollow-up: One yearRegion: North AmericaAge group: AdultsNo. of partic
,
HDM SLIT-tabletMT-02Disease area: Allergic rhinoconjunctivitis and allergic asthmaPhase: II/IIIFollow-up: One yearRegion: EuropeAge group: Adolescents
,
P003Disease area: Allergic rhinoconjunctivitisPhase: IIFollow-up: Up to 76 weeksRegion: Environmental exposure chamber (Europe)Age group: AdultsNo. of
,
MT-12/MATICDisease area: Allergic rhinoconjunctivitisPhase: IIIFollow-up: One yearRegion: North America and EuropeAge group: ChildrenNo. of participan
,
Compliance with guidelinesIn compliance with industry guidelines, more information about all our clinical trials can be found via the freely public re
/our-science/healthcare-professionals/allergy-immunotherapy
Healthcare professionals, Allergy immunotherapy, Allergy-immunotherapy-banner.png
,
Targets the root cause of allergy by stimulating an immune responseAllergy immunotherapy (AIT) is the only treatment of allergic disease that addresse
,
Disease-modifying and protective effectTo achieve long-term sustained effect, where the benefits of the treatment continue after the treatment has end
,
Why has AIT disease-modifying effect?, <p><iframe src="https://www.alk.net/sites/default/files/2024-10/MoA%20AIT%20short%20video.mp4" frameborder="0" allowfulls, videoframe_5652.png, Watch video
,
.h3-bold-heading {
margin: 0;
font-weight: 600;
font-size: 35px;
color: #0a2455;
}
.clinical-trials-card-container {
displa
/terms-and-conditions/privacy-notice/shareholders-proxies-advisors
Privacy notice for shareholders, proxies and advisorsMarch 2025The purpose of this privacy notice is to describe how ALK-Abelló A/S (ALK), as part of , 1. Identity and contact details of the data controller, The legal entity responsible for processing you…
/our-solutions/emergency-medicine
Anaphylaxis, Treatment of acute allergic reactions, emergency_medicine_background_image.jpeg
,
Left, The recommended emergency treatment is an intra-muscular injection of adrenaline followed by an immediate call for medical assistance.ALK has develope, emergency_medicine_text_image.jpeg
,
Learn more about how we collect, extract and process venom from bees and wasps to create venom allergy treatments., ALK From Nature to Medicines_Short version 1080p-ENG.mp4, Watch the video
/terms-and-conditions/privacy-notice/crm-marketing
Privacy notice for CRM – MarketingJanuary 2025According to Article 12 of the General Data Protection Regulation, we must provide you with certain info, 1. Identify and contact details about the data controller, The data controller for the processing descr…
/terms-and-conditions/privacy-notice/job-application
Privacy notice related to your job application at ALKJanuary 2025As part of our recruitment process through EasyCruit, we are required to provide you , 1. Identify and contact details about the data controller, ALK, as the data controller, is responsible…
/terms-and-conditions/privacy-notice/newsletter
Privacy notice related to your subscription to our newsletterJanuary 2025The purpose of our website is to provide information about our company, produ, 1. Identify and contact details about the data controller, ALK, as the data controller, is responsible…